NeuroScientific Biopharmaceuticals (ASX:NSB) has reported encouraging results from two early studies of its StemSmart mesenchymal stromal cell (MSC) therapy in renal transplantation, reinforcing its potential to improve outcomes for patients facing the risks of graft rejection and transplant-related complications. …
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News